Zhi Tong Cai Jing·2025-10-31 07:09Core Viewpoint - Zhaoyan New Drug (603127) experienced a stock price increase of over 4%, reaching HKD 21.66 with a trading volume of HKD 209 million, following the announcement of its financial results for the first three quarters of 2025 [1] Financial Performance - The company reported a revenue of RMB 985 million for the first three quarters of 2025, representing a year-on-year decrease of 26.23% [1] - The net profit attributable to the parent company was RMB 80.71 million, a significant improvement compared to a loss of RMB 70.31 million in the same period last year [1] Order Status - The total new signed orders amounted to approximately RMB 1.64 billion for the first three quarters [1] - As of the end of the reporting period, the total backlog of orders stood at around RMB 2.5 billion [1]